The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review.
Open accessAbstract
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs) for making balanced treatment decisions. Objective: To systematically review the presence of AEs during and after administration of serotonergic psychedelics and 3,4-methyenedioxymethamphetamine (MDMA) in clinical studies. Methods: We systematically searched PubMed, PsycINFO, Embase, and ClinicalTrials.gov for clinical trials with psychedelics since 2000 describing the results of quantitative and qualitative studies. Results: We included 44 articles (34 quantitative + 10 qualitative), describing treatments with MDMA and serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) in 598 unique patients. In many studies, AEs were not systematically assessed. Despite this limitation, treatments seemed to be overall well tolerated. Nausea, headaches, and anxiety were commonly reported acute AEs across diagnoses and compounds. Late AEs included headaches (psilocybin, MDMA), fatigue, low mood, and anxiety (MDMA). One serious AE occurred during MDMA administration (increase in premature ventricular contractions requiring brief hospitalization); no other AEs required medical intervention. Qualitative studies suggested that psychologically challenging experiences may also be therapeutically beneficial. Except for ayahuasca, a large proportion of patients had prior experience with psychedelic drugs before entering studies. Conclusions: AEs are poorly defined in the context of psychedelic treatments and are probably underreported in the literature due to study design (lack of systematic assessment of AEs) and sample selection. Acute challenging experiences may be therapeutically meaningful, but a better understanding of AEs in the context of psychedelic treatments requires systematic and detailed reporting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent critiques highlight notable limitations in many of these studies, [16][17][18][19] including small sample sizes, assessments by raters likely to be functionally unblinded, an open or waitlist comparator design, and an inadequate assessment of adverse events (AEs).”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“No serious TEAEs were reported in the current study; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs compared with niacin, with these severe AEs being known effects of psilocybin.17”
From Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Controlled clinical trials with psilocybin, as well as other psychedelics, have occasionally reported increases in suicidality after treatment, sometimes with extremely brief information about treatment-relatedness (Breeksema et al., 2022; Goodwin et al., 2022).”
From Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response (2024) · cites this paper as Breeksema et al., 2022
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of SAEs and low rates of TRAEs that were mild or moderate and self-limiting is also consistent with prior studies of PAT, and supports the hypothesis that PAT has an acceptable safety profile for a selected group of people with MAUD [55].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“[100] have drawn attention to a potential underreporting of adverse events in PAT studies due to a lack of systematic assessment and disclosure.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 4×
“Two RCTs systematically assessed AEs (Mitchell et al., 2021; Mithoefer et al., 2019), another study employed the UKU scale of secondary effects; this was the only study reporting AE severity (Oehen et al.”
BackgroundResultInfluentialRetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 15×
“(2014) EOLA: End-of-life anxiety; LSD: lysergic acid diethylamide; PTSD: post-traumatic stress disorder; TRD: treatment-resistant depression. occurred more often in the MDMA than in the placebo groups, with some exceptions (e.g., one RCT found a slightly higher prevalence of anxiety and fatigue in the placebo group) (…”
BackgroundResultInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · cited 14×
“(2014) EOLA: End-of-life anxiety; LSD: lysergic acid diethylamide; PTSD: post-traumatic stress disorder; TRD: treatment-resistant depression. occurred more often in the MDMA than in the placebo groups, with some exceptions (e.g., one RCT found a slightly higher prevalence of anxiety and fatigue in the placebo group) (…”
BackgroundInfluentialGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“Open-label studies investigated the treatment of treatment-resistant depression (TRD; Carhart-Harris et al., 2016, 2018), AUD (Bogenschutz et al., 2015), tobacco smoking (Johnson et al., 2014), and demoralization in older AIDSsurvivors (Anderson et al., 2020).”
BackgroundTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 7×
“, 2016), two RCTs on MDD (Carhart-Harris et al., 2021; Davis et al., 2020), one RCT on migraine headaches (Schindler et al.”
BackgroundResultInfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 15×
“Quality appraisal Two studies did not report on AEs (Grob et al., 2011; Moreno et al., 2006).”
BackgroundInfluential
Research works printed but not linked: 6
- Kirkpatrick M, De Wit H (2014) The acute effects of MDMA in social contexts. Neuropsychopharmacology 39: S466.
- Lindsay B (2022) Health Canada announces review of all MDMA trials as complaint alleges major flaws and safety issues. CBC News. Available at: https://www.cbc.ca/news/canada/british-columbia/health-canada-mdma-trial-complaints-flaws-safety-issues-1.6409849 (accessed 8 April 2022).
- Mithoefer MC, Doblin R, Mithoefer A, et al. (2013a) A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Santa Cruz, CA: MAPS.
- Peryer G Golder S Junqueira D et al. (2021) Chapter 19: Adverse effects. In: Higgins JPT Thomas J Chandler J et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated February 2021). Cochrane. Available at: http://www.training.cochrane.org/handbook (accessed 21 March 2022).
- Vizeli P, Holze F, Schmid Y, et al. (2019) At ease-subjective effects of MDMA in placebo-controlled studies with healthy subjects. Psychother Psychosom 88: 133–134.
- 10.1038/sj.npp.1395197 · DOI · Paper page
Cited by
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023) · PLOS ONE · doi:10.1371/journal.pone.0293349 · Cited by 185
McNamee, S., Devenot, N., & Buisson, M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.0099 · Cited by 168
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2024.2546 · Cited by 156
History repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137
Metadata
- Authors
- Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A.
- Affiliations
- University Medical Center Groningen (NL)
- Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands
- Leiden University Medical Center (NL)
- Corresponding author
- Breeksema, Joost J
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-08-26
- Volume
- 36
- Issue
- 10
- Pages
- 1100-1117
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC9548934
- OpenAlex
- W4293194637
- Semantic Scholar
- 3be719319c74dcced429f26ce5a53968e97eb19f
- Cited by
- 178
- References
- 116
- Citations by year
- 2026: 29 · 2025: 47 · 2024: 73 · 2023: 29
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- adverse events, serotonergic psychedelics, MDMA, psilocybin, lysergic acid diethylamide, ayahuasca, psychedelic therapy, adverse event reporting, premature ventricular contractions, tolerability
- MeSH terms
- Hallucinogens, Headache, Humans, Lysergic Acid Diethylamide, Psilocybin, N-Methyl-3,4-methylenedioxyamphetamine, Banisteriopsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. https://app.cochat.ai/papers/10.1177/02698811221116926
- The paper
- Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221116926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
